[{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GT-02329","moa":"GCase level","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GT-00513","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"GT-02287","moa":"GBA1","graph1":"Neurology","graph2":"Phase II","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Gain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gain Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Gain Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
